Previous 10 | Next 10 |
The findings, including encouraging preliminary efficacy data in various tumor types, were presented during the 34th EORTC-NCI-AACR Symposium PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that preliminary results from th...
PLANEGG / MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner, GSK plc (GSK), provided an update on the ContRAst phase III program for otilimab as a potential treatment of moderate to severe rheumatoid arthritis (R...
The American Depository Receipts of MorphoSys AG ( NASDAQ: MOR ) dropped ~10% on Monday as both Deutsche Bank and Kempen downgraded the German biotech following weak sales data for the company’s cancer therapy Monjuvi. MorphoSys ( MOR ) has partnered with U....
MorphoSys ( NASDAQ: MOR ) is down -9.57% as of 1pm ET after Deutsche Bank downgraded the stock from a Hold to Sell. The downgrade comes a few days after the biopharmaceutical company lowered its FY22 outlook for cancer drug Monjuvi' U.S. net product sales citing "incre...
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 Preliminary Q3 2022 Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million) Anticipated full year 2022 Monjuvi U.S. net product sales of approximately US$ 90 million...
MorphoSys AG (MOR) Q2 2022 Earnings Conference Call August 4, 2022 08:00 AM ET Company Participants Julia Neugebauer - IR Jean-Paul Kress - CEO Malte Peters - Chief Research & Development Officer Sung Lee - CFO Joseph Horvat - U.S. General Manager ...
Image source: The Motley Fool. MorphoSys AG (NASDAQ: MOR) Q2 2022 Earnings Call Aug 04, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: MorphoSys AG (MOR) Q2 2022 Earnings Call Transcript
MorphoSys press release ( NASDAQ: MOR ): 1H GAAP EPS of -€10.47. Revenue of €100.9M. For further details see: MorphoSys GAAP EPS of -€10.47, revenue of €100.9M
– Monjuvi ® U.S. net product sales of US$ 23.3 million (€ 21.7 million) for the second quarter 2022, a 25% Q-Q growth and 29% Y-Y growth – Efficacy and safety data of pelabresib for potential treatment improvement in myelofibrosis presented at EHA...
Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 28, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) will publish its results for the second quarter and first half year 2022 results on August 3, 2022 at 10:00 pm CEST (9:00 pm BST; 4:00 pm EDT). MorphoSys' Management tea...
News, Short Squeeze, Breakout and More Instantly...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares (“ADSs”) from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Ex...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...